Trial
NCT02680951
Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Emory University
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
Dasatinib
Why stopped
Withdrawn due to lack of participants.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-04-19